Home/Pipeline/ANV200

ANV200

Autoimmune Diseases

PreclinicalActive

Key Facts

Indication

Autoimmune Diseases

Phase

Preclinical

Status

Active

Company

Anaveon

About Anaveon

Anaveon is a Swiss, private biotech founded in 2017, operating in the late preclinical stage with a focus on precision biologics for immune-mediated diseases. Its lead asset, ANV200, is an engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells, with clinical testing planned in the near future. The company is led by a seasoned executive team with deep immunology and biopharma business development expertise, positioning it to advance its pipeline and seek strategic partnerships for growth.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Gavocabtagene autoleucel	astellas	Phase 1/2	Active
TYK-101	TYK Medicines	Phase 1	Active
HCB206	HanchorBio	Preclinical	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active